The Safety, Tolerability and Efficacy of Dronabinol, for the Treatment of Nausea and Vomiting in Familial Dysautonomia
Status:
Withdrawn
Trial end date:
2019-03-22
Target enrollment:
Participant gender:
Summary
This is a pilot clinical trial of dronabinol to treat disabling attacks of nausea and
vomiting in patients with familial dysautonomia (FD, also known as Riley Day syndrome or
hereditary sensory and autonomic neuropathy type III). FD is a rare autosomal recessive
disease in which the growth and development of selective nerves is impaired. Patients with FD
suffer recurrent uncontrollable nausea and vomiting crises accompanied by skin flushing,
tachycardia and arterial hypertension. Current treatments of nausea are ineffective or have
intolerable side sides. Our long-term goal is to treat nausea effectively and without side
effects, a therapeutic intervention that would markedly improve the quality of life of
patients with FD.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health